Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.47 USD | -2.95% | -15.00% | 0.00% |
Apr. 25 | Nasdaq's revenue beats on strong demand for fintech products | RE |
Mar. 26 | Kyverna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 3.75M | Sales 2025 * | 5M | Capitalization | 667M |
---|---|---|---|---|---|
Net income 2024 * | -130M | Net income 2025 * | -199M | EV / Sales 2024 * | 125 x |
Net cash position 2024 * | 197M | Net cash position 2025 * | 142M | EV / Sales 2025 * | 105 x |
P/E ratio 2024 * |
-4.86
x | P/E ratio 2025 * |
-3.91
x | Employees | 96 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.27% |
1 day | -2.95% | ||
1 week | -15.00% | ||
Current month | -37.72% | ||
1 month | -37.77% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Maag
CEO | Chief Executive Officer | 56 | 22-10-12 |
Ryan Jones
DFI | Director of Finance/CFO | 36 | 17-12-31 |
Dominic Borie
CTO | Chief Tech/Sci/R&D Officer | 61 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 18-08-31 |
Ian Clark
CHM | Chairman | 62 | 21-09-14 |
Dan Spiegelman
BRD | Director/Board Member | 65 | 21-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 15.47 | -2.95% | 705,577 |
24-04-25 | 15.94 | -9.99% | 587,880 |
24-04-24 | 17.71 | -7.71% | 222,597 |
24-04-23 | 19.19 | -1.59% | 123,070 |
24-04-22 | 19.5 | +7.14% | 284,678 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 667M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- KYTX Stock